Insider · CIK 0001854362
Sumit Aggarwal
Files at ELOX (Eloxx Pharmaceuticals, Inc.). First filing -, latest -.
Sumit Aggarwal files SEC Form 4 as CEO, president, director and 10% owner at ELOX (Eloxx Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sumit Aggarwal has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 24 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +328,833 | $0.00 | $0 | 328,833 | Jun 10, 2026 |
| Aug 14, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +196,880 | $0.00 | $20 | 396,810 | May 8, 2026 |
| Sep 19, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Common Stock | +1,000,000 | $0.00 | $0 | 1,396,810 | May 8, 2026 |
| Jan 24, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +15,000 | - | - | 1,411,810 | May 8, 2026 |
| Feb 28, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +260,946 | $0.15 | $39k | 1,672,756 | May 8, 2026 |
| Feb 6, 2022 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +42,790 | $0.00 | $0 | 42,790 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,790 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +42,790 | - | - | 42,790 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,580 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,580 | - | - | 35,580 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -24,810 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +24,810 | - | - | 24,810 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -68,700 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +68,700 | - | - | 68,700 | May 8, 2026 |
| Aug 14, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -60,390 | $0.00 | $0 | 0 | May 8, 2026 |
| Aug 14, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -68,700 | $0.00 | $0 | 0 | May 8, 2026 |
| Aug 14, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | May 8, 2026 |
| Aug 14, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -42,790 | $0.00 | $0 | 0 | May 8, 2026 |
| Sep 19, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,597,090 | $0.00 | $0 | 3,597,090 | May 8, 2026 |
| Jan 24, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -15,000 | $0.00 | $0 | 15,000 | May 8, 2026 |
| Feb 28, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -260,946 | $0.00 | $0 | 3,336,144 | May 8, 2026 |
| Jan 24, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +30,000 | $0.00 | $0 | 199,930 | Jan 28, 2025 |
| Jan 24, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -30,000 | $0.00 | $0 | 30,000 | Jan 28, 2025 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Common Stock | +165,000 | $0.00 | $0 | 169,930 | Oct 17, 2024 |
Questions about Sumit Aggarwal
Answered from the filings on this page, as of the latest one.
Is Sumit Aggarwal buying or selling?
Sumit Aggarwal has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sumit Aggarwal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sumit Aggarwal has 0.
Where does Sumit Aggarwal file Form 4?
Sumit Aggarwal has filed Form 4 at ELOX (Eloxx Pharmaceuticals, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.